Entrectinib, a highly potent pan-Trk, ROS1, and ALK inhibitor, has broad-spectrum, histology-agnostic anti-tumor activity in molecularly defined cancers. (December 2016) - Wei, G.; Patel, R.; Walsh, C.; Barrera, M.; Fagan, P.; Murphy, D.; Christiansen, J.; Shoemaker, R.; Hornby, Z.; Li, G.G.